secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2025-02-24T23:59:59+00:00
Accession:  0000950170-25-025640
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 3.03, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Karyopharm files 1-for-15 reverse stock split effective Feb 25 to meet Nasdaq bid price rule
--------------------------------------------------------------------------------

- Reverse stock split 1-for-15 effective Feb 25, 2025 at 5pm ET; post-split trading starts Feb 26.
- Authorized shares reduced to 53,333,333; no fractional shares, cash paid in lieu.
- Equity awards, warrants, and convertible notes adjusted proportionally.
- New CUSIP number for common stock after split is 48576U205.
- Purpose: regain compliance with Nasdaq minimum $1.00 bid price continued listing requirement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000095017025025640/0000950170-25-025640-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000095017025025640/kpti-20250224.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-025640

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer